SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Wallace, D J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wallace, D J
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Apheresis for lupus erythematosus

D J Wallace

Cedars-Sinai/UCLA School of Medicine, USA; Department of Rheumatic and Arthritis Diseases, 8737 Beverly Blvd 203, Suite 203, Los Angeles, CA 90048, USA

Indications for the use of apheresis technologies in managing lupus erythematosus have undergone numerous conceptual changes since the procedure was automated in the 1960s and first attempted for systemic lupus erythematosus (SLE) in 1974. Once thought to be a promising treatment for a variety of aspects of SLE, apheresis has been relegated to occupying a few important niches as an adjunct in managing the disorder. This article will review the history, physiology and rationale of apheresis pertaining to SLE. A focused critical review of pertinent literature is presented, along with specific recommendations relating to the place of apheresis in the lupus therapeutic spectrum.

Key Words: plasmapheresis • systemic lupus erythematosus • treatment

Lupus, Vol. 8, No. 3, 174-180 (1999)
DOI: 10.1191/096120399678847669
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
P. Bartolucci, S. Brechignac, P. Cohen, V. Le Guern, and L. Guillevin
Adjunctive plasma exchanges to treat neuropsychiatric lupus: a retrospective study on 10 patients
Lupus, October 1, 2007; 16(10): 817 - 822.
[Abstract] [PDF]

Home page
 Ann Rheum DisHome page
G H Stummvoll, M Aringer, J S Smolen, S Schmaldienst, E Jimenez-Boj, W H Horl, W B Graninger, and K Derfler
IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study
Ann Rheum Dis, July 1, 2005; 64(7): 1015 - 1021.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
J S Blake and L Butani
Rapidly progressive lupus glomerulonephritis and concomitant microangiopathy in an adolescent
Lupus, August 1, 2002; 11(8): 533 - 535.
[Abstract] [PDF]

Home page
 LupusHome page
S B Matthews, G Kallarackal, M Shortt, and M H Pritchard
Chemoadsorbtion apheresis: a useful therapy in lupus nephritis
Lupus, January 1, 2002; 11(1): 64 - 65.
[PDF]

Home page
 Ann Rheum DisHome page
B BERNER, A K SCHEEL, V SCHETTLER, K M HUMMEL, M A REUSS-BORST, G A MULLER, E OESTMANN, H-P LEINENBACH, and M HEPPER
Rapid improvement of SLE-specific cutaneous lesions by C1q immunoadsorption
Ann Rheum Dis, September 1, 2001; 60(9): 898 - 899.
[Full Text] [PDF]

Home page
 LupusHome page
D J Wallace
Apheresis for lupus erythematosus: state of the art
Lupus, March 1, 2001; 10(3): 193 - 196.
[Abstract] [PDF]


Advertisement